Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001197295 | SCV001367945 | likely pathogenic | Hereditary thrombocytopenia and hematologic cancer predisposition syndrome | 2024-06-24 | reviewed by expert panel | curation | The 1003C>T (p.Gln335Ter) variant is a nonsense variant that is not expected to result in nonsense-mediated mRNA decay, but the predicted truncated/altered region (removes aa 335-480) is critical to protein function (PVS1_Strong). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). The variant has not been reported in patients with familial platelet disorder with predisposition to hematologic malignancies in the literature, to the best of our knowledge; however one unpublished proband meeting at least one of the RUNX1 phenotype criteria is noted (PS4_Supporting; SCV000807750.1). This variant is a nonsense/frameshift variant that is downstream of c.98 (PM5_Supporting). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1_Strong, PM2_supporting, PS4_Supporting, PM5_supporting. |
Prevention |
RCV000680379 | SCV000807750 | likely pathogenic | not provided | 2016-08-18 | criteria provided, single submitter | clinical testing | |
Genetic Service Laboratory, |
RCV002472312 | SCV002758750 | likely pathogenic | Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 | 2022-12-06 | criteria provided, single submitter | clinical testing | The variant is a nonsense variant that is not expected to result in nonsense-mediated mRNA decay (c.914-c.1440), but the predicted truncated/altered region (removes aa 335-480) is critical to protein function (PVS1_Strong). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_Supporting). The variant has been reported in patients with familial platelet disorder with predisposition to hematologic malignancies in the literature (Myeloid Malignancy VCEP and ClinVar). (PS4_Moderate; SCV001367945.1, SCV000807750.1). |